Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

132.65USD
21 Aug 2017
Change (% chg)

$0.02 (+0.02%)
Prev Close
$132.63
Open
$132.28
Day's High
$132.67
Day's Low
$132.22
Volume
178,577
Avg. Vol
1,801,006
52-wk High
$137.07
52-wk Low
$109.32

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $355,978.91
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.53

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.43 31.45 32.56
EPS (TTM): 5.91 -- --
ROI: 13.49 15.33 14.89
ROE: 22.63 16.35 16.13

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

Aug 18 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Judge tosses 53 plaintiffs' claims against J&J over Risperdal

Johnson & Johnson has convinced a federal judge that a recent U.S. Supreme Court ruling requires the dismissal of claims in Missouri state court by 53 out-of-state plaintiffs over injuries they blame on the antipsychotic drugs Risperdal and Invega.

Aug 11 2017

BRIEF-Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation

* Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10

Aug 09 2017

BRIEF-DePuy Synthes collaborates with Medical Enterprises Distribution to co-market ME1000

* DePuy Synthes says exclusive agreement with Medical Enterprises Distribution to co-market ME1000 surgical impactor for use in Total Hip Arthroplasty

Aug 07 2017

J&J loses another round in fight to toss Missouri talc cases

Johnson & Johnson has suffered another setback in its efforts to use a recent U.S. Supreme Court ruling to dismiss claims by hundreds of women and their family members in Missouri state court that its talc products can cause ovarian cancer.

Aug 04 2017

FDA panel votes against approval of J&J arthritis drug

The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 03 2017

FDA panel votes against approval of J&J arthritis drug

The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 02 2017

UPDATE 1-U.S. FDA panel votes against approval of J&J arthritis drug

Aug 2 The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.

Aug 02 2017

Earnings vs. Estimates